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Cardiovascular disease is a major cause of morbidity and mortality among people with type 2 diabetes mellitus.The peroxisome
proliferator-activated receptor (PPAR) agonists have a signiﬁcant role on glucose and fat metabolism. Thiazolidinediones (TZDs)
are predominantly PPARγ agonists, and their primary beneﬁt appears to be the prevention of diabetic complications by improving
glycemic control and lipid proﬁle. Recently, the cardiovascular safety of rosiglitazone was brought to center stage following meta
analyses and the interim analysis of the RECORD trial. Current evidence points to rosiglitazone having a greater risk of myocardial
ischemic events than placebo, metformin, or sulfonylureas. This review article discusses the mechanism of action of PPAR agonists
andcorrelatesitwithclinicalandlaboratoryoutcomesinthepublishedliterature.Inaddition,thisreviewarticleattemptstodiscuss
some of the molecular mechanisms regarding the association between TZDs therapy and the nontraditional cardiovascular risks.
Copyright © 2009 Ahmad Aljada et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Diabetes Mellitus has emerged as a global burden, as World
Health Organization (WHO) has estimated a prevalence of
more than 300 million people by the year 2025. Diabetes
is associated with a 2–4 fold increased risk for developing
unstable angina and myocardial infarction (MI) with sub-
sequent increased mortality and morbidity [1, 2]. Endothe-
lial inﬂammation, dyslipidemia, ﬂuid retention, edema are
among the important factors that play a role in increasing
cardiovascular risk in patients with diabetes mellitus.
PPAR agonists have several metabolic activities which
can signiﬁcantly aﬀect cardiovascular risk. Rosiglitazone
and pioglitazone are PPARγ agonists that improve glycemic
controland havebeenshowntoexertpossiblecardiovascular
beneﬁts. However, recent studies have shown that rosigli-
tazone is associated with an increased risk of heart failure,
acute MI (AMI) and death as a result of cardiovascular
complications [3, 4]. PPARs belong to the nuclear receptor
superfamily. They are ligand-activated transcription factors
and regulate transcription of target genes by forming het-
erodimers with the retinoid X receptor (RXR) and binding
to speciﬁc PPAR response elements (PPREs) in the promoter
region of target genes [5]. Three receptor isoforms have
been identiﬁed, PPARα,P P A R γ,a n dP P A R δ. They mediate
distinct eﬀects on blood vessel wall, liver, adipose tissue and
skeletal muscle (Table 1)[ 6–8].
TZDs decrease insulin resistance, increase peripheral
glucose use, reduce hepatic glucose output and as a
result improve overall blood glucose control. In addition,
PPARγ ligands have beneﬁcial eﬀects on plasma lipids.
Both pioglitazone and rosiglitazone increase serum levels
of high-density lipoprotein (HDL) and reverse cholesterol
transport.Pioglitazonealsoreducesplasmatriglyceridelevels
markedly [6–9]. Pioglitazone has more favorable eﬀects on
triglycerides than rosiglitazone, although the clinical impact
of this ﬁnding remains unclear and seems insigniﬁcant
in clinical practice [10, 11]. The mechanisms underlying
diﬀerentialeﬀectsofpioglitazoneandrosiglitazoneonserum
lipids may derive from diﬀerent degrees of selectivity for
PPARγ. Rosiglitazone acts more selectively as a PPARγ ago-
nist while pioglitazone has some additional PPARα agonist
activity [12–14]. The diﬀerences between pioglitazone and
rosiglitazone remain unknown, probably due to mechanisms
related both to kinetic properties and pleiotropism of these
molecules. Further studies are needed to better understand2 PPAR Research
Table 1: Eﬀects of PPARα and PPARγ on vessel wall, liver, adipose and muscle tissues [6–8].
Vessel wall Liver Adipose Muscle
PPARα
↓ Inﬂammation
Reverses cholesterol
transport
↓ Triglyceride
↑ HDL; ↓ Small dense
LDL
↑ Adipogenesis ↑ FFA oxidation
PPARγ
↓ Inﬂammation
Reverses cholesterol
transport
↑ fatty acid storage
↑ Adiponectin
↑ Fatty acid storage
↑ Glucose uptake
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Figure 1: Hazard ratio of chronic heart failure (CHF), acute
myocardialinfarction(AMI)andallcausemortalityforuseofTZDs
versus other oral hypoglycemic drugs (95% CI). This ﬁgure shows
the association of TZDs with CHF, AMI and mortality, compared
with other oral hypoglycemic agents; ∗P<. 001; +P<. 01 [19].
the mechanisms underlying diﬀerential eﬀects of these drugs
onlipidmetabolismandthemeaningoftheseeﬀectsinterms
of cardiovascular prevention. PPAR “oﬀ-target” signalling
remains a possibility and requires further elucidation.
2 .Ef f ec t so fP P A RA g o n is t so n
CardiovascularEvents
Pioglitazone Eﬀect on Regression of Intravascular Sono-
graphic Coronary Obstruction Prospective Evaluation
(PERISCOPE) was designed to compare the eﬀects of
Glimepride with pioglitazone on atherosclerosis in patients
withtype2diabetes. Itshowedthatpioglitazone signiﬁcantly
lowered the rate of progression of atherosclerosis in these
patients [15]. Similarly, the PROactive study (PROspective
pioglitAzone Clinical Trial In macroVascular Events) is a
large-scale prospective clinical trial examining the eﬀects
of TZDs on cardiovascular outcomes. In this placebo-
controlled study of 5238 patients with type 2 diabetes and
signiﬁcant macrovascular disease at baseline, patients were
randomized to pioglitazone-treated or placebo groups. In
thisstudy,pioglitazonesigniﬁcantlyreducedasecondaryend
point (all-cause mortality, nonfatal myocardial infarction
(MI), and stroke; hazard ratio, 0.84; P = .03) [16].
The pioglitazone-treated group also showed signiﬁcant
changes in lipid proﬁle (increased HDL cholesterol and
LDL cholesterol and decreased triglycerides). However,
in PROactive study, pioglitazone increased the incidence
of heart failure with a relative risk of 1.5% (P = .007).
Hence, potential unwanted cardiac eﬀects require caution
and further rigorous clinical evaluation, because they may
have masked any beneﬁt from actions on lipid proﬁle and
inﬂammation. Similarly, the results of an interim analysis
of the Rosiglitazone Evaluated for Cardiac Outcomes and
Regulation of Glycemia in Diabetes (RECORD) study which
was designed to evaluate the eﬀect of rosiglitazone on
cardiovascular morbidity and death in approximately 4500
patients showed a signiﬁcant risk of heart failure (hazard
ratio 2.15; with a 95% conﬁdence interval from 1.30 to
3.57, P = .003) in those assigned to rosiglitazone group
compared with metformin and sulfonylurea. It did not show
any increase in AMI [17, 18].
Patients on TZD monotherapy as well as or in combi-
nation with other agents were at increased risk of chronic
heart failure (CHF). This increased risk was identiﬁed
only with rosiglitazone. A signiﬁcant association with CHF
risk remained for patients treated with rosiglitazone even
among patients with no history of CHF. In addition, TZDs
treatment, appeared to be limited to rosiglitazone, was
associatedwithanincreasedriskofAMIversususersofother
oral hypoglycemic agent combinations. Both rosiglitazone
monotherapy and combination therapy were associated
with an increased risk of death compared with other oral
hypoglycemic agent combination therapies (Figure 1)[ 19].
Similarly, results from the Diabetes Outcome Progression
Trial (ADOPT) showed diﬀerences in the adverse events
among patients receiving monotherapy with rosiglitazone;
metformin; glyburide although there was no signiﬁcant
diﬀerence in the overall mortality between the three groups.
Rosiglitazone group was also signiﬁcantly associated with
edema and the use of loop diuretics than was either
metformin or glyburide and higher levels of LDL cholesterol
although the death rates were similar, there were other sta-
tistically signiﬁcant diﬀerences in adverse outcomes within
the three drugs. Rosiglitazone was signiﬁcantly associated
with CHF, edema and raised LDL compared to metformin
and glyburide (Figure 2). Various studies compared the
diﬀerences in the treatment outcomes of pioglitazone and
rosiglitazone (Table 2)[ 19–23]. Broadly, pioglitazone has a
better overall clinical and laboratory outcome as compared
to rosiglitazone. However, a common limitation was a high
drop-out rate of patients in these studies.PPAR Research 3
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Figure 2: Number of events with antidiabetic drugs. The ﬁgure
shows the eﬀect of antidiabetic drugs (rosiglitazone, metformin,
and glyburide) on various cardiovascular adverse events; ∗P<
.01; +P<. 05 for the comparison between metformin and
glyburide treatment groups and the rosiglitazone group. The ﬁgure
is developed from the data of adverse events shown in the Diabetes
Outcome Progression Trial (ADOPT) trial [7].
Table 2: The eﬀe c to fT Z D so nC Vr i s k . The table shows a
comparison between rosiglitazone and pioglitazone on lipid proﬁle
and HbA1c levels in various studies [19–23].
TZDs versus placebo Pioglitazone Rosiglitazone
Total cholesterol Neutral Raised
LDL Neutral Raised
HDL Raised Raised
Triglycerides Reduced Neutral
HbA1c ↓ 1–1.5% ↓ 1–1.5%
TheadverseeﬀectsoffullPPARγ agonistshavereinforced
the need to identify additional therapies that improve
insulin sensitivity and treat hyperlipidemia in addition
to lowering blood pressure. In this regard, several lines
of clinical evidence support the use of two Angiotensin
receptor blockers (ARBs), telmisartan and irbesartan, in
treating hyperlipidemia and insulin resistance [24]. In
the Ongoing Telmisartan Alone and in Combination with
RamiprilGlobalEndpointTrial(ONTARGET),subjectswith
increased risk for cardiovascular events were randomized to
receive telmisartan, ramipril, or a combination of telmis-
artan and ramipril, while in the companion Telmisartan
Randomized Assessment Study in ACE-Intolerant Subjects
with Cardiovascular Disease (TRANSCEND) trial, subjects
intolerant to ACE inhibitors were randomized to telmisartan
or placebo [25]. This study included 5926 participants who
were randomly assigned to telmisartan 80mg/day (n =
2954) or placebo (n = 2972). The primary endpoint
was the composite of cardiovascular death, MI, stroke or
hospitalization due to heart failure. The secondary outcome
excluded heart failure. Median follow-up was 56 months
[26]. There was no diﬀerence in the primary composite
endpoint of cardiovascular death, myocardial infarction,
stroke, or admission to hospital for heart failure. These stud-
ies indicate that Angiotensin converting enzyme inhibitors
(ACEi) will probably remain the ﬁrst choice due to the
greater body of supportive evidence.
3. PPARα andCardiovascularEvents
PPARα by regulating the expression of proteins involved
in the transport and β-oxidation of free fatty acids (FFAs)
plays a pivotal role in the regulation of lipid and glucose
metabolism [27]. Fibrates, widely used to treat hyper-
triglyceridemia, are weak activators of PPARα.T h e yl o w e r
circulating triglyceride levels by increasing the activity of
lipoprotein lipase (LPL) which hydrolyzes triglycerides [28].
PPARα agonists increase the gene expresson of LPL and
up regulate Apo A-I and A-II synthesis which are major
apoproteins of the HDL fraction in the liver and resulting
in increased serum HDL levels [29, 30]. Data from large
clinical trials suggested that ﬁbrates reduce cardiovascular
risk, particularly in high-risk populations. In the Veterans
Aﬀairs High-Density Lipoprotein InterventionTrial (VA-
HIT), gemﬁbrozil signiﬁcantly decreased coronary heart dis-
ease (CHD) mortality by 41% as compared to those patients
with diabetes mellitus receiving the standard treatment [31].
In the Helsinki Heart Study (HHS), gemﬁbrozil reduced
coronary risk by 34% in the overall study population.
Coronary artery disease (CAD) events occurred in 3.4%
and 10.5% of gemﬁbrozil and placebo treated patients
with diabetes, respectively, although this diﬀerence did not
achieve statistical signiﬁcance [32, 33]. Similarly, Fenoﬁbrate
Intervention and Event Lowering in Diabetes (FIELD) study
investigated the eﬀects of fenoﬁbrate on cardiovascular risk
in 9795 patients with type 2 diabetes. Fenoﬁbrate caused an
11% reduction in total cardiovascular events. These studies
suggest that PPARα agonists are possibly beneﬁcial in the
clinical scenario [34].
Several studies have shown that pioglitazone increased
serum HDL-cholesterol and decreased triglycerides, and
pioglitazone produced more favorable lipid proﬁles than
rosiglitazone in patients with type 2 diabetes mellitus [13,
35]. Notably, Szapary et al. have shown that pioglitazone
treatment for 12 weeks signiﬁcantly increased Apo-AII by
7.7% [35] while Qin et al. demonstrated that pioglitazone
stimulates Apo-AI production in HepG2 cells by through
PPARα activation [12]. They have also shown that piogli-
tazone increases apoA-II synthesis and mRNA expression in
HepG2 cells. These ﬁndings support the notion that piogli-
tazone increases apoA-I and apoA-II through its PPARα
binding.
4. TZDs andNonconventional Cardiovascular
Risk Factors
To establish a possible role of pioglitazone and rosiglitazone
in prevention of cardiovascular disease appears the primary4 PPAR Research
Table 3: Eﬀects of PPARγ and PPARα agonists on inﬂammatory mediators. Table shows the eﬀe c to fP P A R γ and PPARα receptors
modulation on the expression of various inﬂammatory mediators. ICAM: intercellular adhesion molecule; VCAM: vascular cell adhesion
molecule; IL: Interleukin; TNF-α: Tumor necrosis factor-α; MMP-9: Matrix metalloproteinase-9; IFN: interferon; NF: Nuclear factor; iNOS:
Inducible nitric oxide synthase; CRP: C-Reactive protein; CD40L: CD40 Ligand; LOX-1: low-density lipoprotein receptor-1; AP-1: Activator
protein-1 [29, 30, 38–58].
PPARγ agonists reduce/decrease PPARα agonists reduce/decrease
Endothelium ICAM, VCAM, superoxide
generation ICAM, VCAM, E-selectin
Macrophage IL-1, IL-2, TNFα, MMP-9,
IFN-γ,N F κB, iNOS IL-1, IL-2, TNFα, MMP-9, IFN-γ
Serum/Plasma CRP, MMP-9, IL-6, soluble
CD40L IL-6, Fibrinogen, CRP, MIF
Vascular smooth muscle cells VEGF, MMP-9, IL-1β,I L - 6 ,
TGFβ, LOX-1, TNFα
IL-1β, IL-6, ﬁbrinogen-β,
prostaglandin, NFκB, AP-1
issue in clinical practice. A novel interest is developing in the
so-callednonconventionalcardiovascularriskfactorsinclud-
ing inﬂammation, homocysteine (HCT) and lipoprotein
(Lp(a)). In recent years it has been established that inﬂam-
mation has a pathogenic role in atherosclerosis. Several
studies described the antiinﬂammatory properties of PPARγ
and PPARα agonists which ultimately inhibit atherosclero-
sis by decreasing the expression of several inﬂammatory
mediators involved in macrophage activation and vascular
smooth muscle cells (VSMCs) proliferation (Table 3). Again,
the possibility of PPAR “oﬀ-target” signaling exists in several
of these studies describing the antiinﬂammatory eﬀects
of PPAR. A clear distinction whether these properties are
mediated through PPARγ or PPARα was not established
as well in many of these studies described in Table 3.
Several studies have suggested a possible predictive asso-
ciation between Lp(a), thoracic aortic atherosclerosis and
stroke. Hyperhomocysteinemia seems to be an indepen-
dent factor for atherothrombotic events both in diabetic
and nondiabetic patients. Treatment with pioglitazone in
subjects with type 2 diabetes and metabolic syndrome
for 12 months provided a signiﬁcant decrease in Lp(a)
concentrationdespiteasubstantialneutralityofrosiglitazone
plusmetformincombination;HCTsigniﬁcantlydecreasedin
therosiglitazoneplusmetformingroupafter12months[36].
Similarly, rosiglitazone reduced Lp(a) despite a signiﬁcant
increase in ﬁbrinogen [37].
5. FutureStudies
The cardiovascular beneﬁt-risk ratio of individual PPAR
agonists is not completely clear. The results of data analysis
of the RECORD study showed an increased risk of heart
failure in the rosiglitazone group compared with metformin
and sulfonylurea. It did not show any increase in AMI
[17, 18]. These results suggest increased cardio toxic eﬀects
with the use of rosiglitazone. Furthermore, any potential
antiatherosclerotic beneﬁts must be weighed against the
increased risk of CHF. Several ongoing studies may provide
more information including the Bypass Angioplasty Revas-
cularization Investigation 2 Diabetes (BARI-2D) which is
a randomized trial to study comparing insulin-stimulating
medication versus medication that sensitizes the body to
available insulin in patients with type 2 diabetes and coro-
nary artery disease [59]. Another ongoing study is the Action
toControlCardiovascularRiskinDiabetes(ACCORD).This
is a clinical trial of patients with type 2 diabetes whose
baseline HbA1c levels are less than 7.5% and at high risk
for CVD events due to CVD risk factors or previous CVD
events. The ACCORD study is examining whether aggressive
glucose lowering using a variety of strategies prevents CVD
events in patients with type 2 diabetes in order to support
future clinical guidelines for diabetes management in older
adults. Currently, no PPARδ agonists are clinically approved
at the present moment, but they may be beneﬁcial for the
treatment of cardiovascular disorders and improve overall
cardiovascular risk assessment.
Ongoing Phase II clinical trials of GW-501516, a PPARδ
agonist for the potential treatment of dyslipidemia by
GlaxoSmithKline and Ligand are soon to be released. GW-
501516 may prove to be a suitable alternative for the
treatment of the cardiovascular disease and improve overall
cardiovascular risk assessment. Interestingly, GW501516
suppresses IL-6-mediated hepatocyte acute phase reaction
via STAT3 inhibition [60].
6. Conclusions
The ﬁndings reviewed in this article suggest that the
mechanisms of PPAR agonists have an excellent glucose
and lipid control by their eﬀects on vasculature, muscle
and adipose tissue. The in vitro studies also show their
eﬀects by improving lipid proﬁle, maintaining euglycemia,
suppressing various inﬂammatory mediators, HCT, Lp(a),
and preventing the progression of atherosclerosis. However,
when clinical trials are reviewed, they do not reﬂect very well
withthebeneﬁcialactionsincellandanimalmodels.Rosigli-
tazone has shown adverse eﬀects on heart failure, mortality,
and abnormal lipid proﬁle. Pioglitazone is associated with
increased risk of heart failure due to edema. Furthermore,
pioglitazone has been shown to reduce the cardiovascular
risk in patients with established atherosclerotic vascular
disease. Pioglitazone has also a favorable eﬀect on lipid
proﬁle by stimulating apoA1 production because it hasPPAR Research 5
some additional PPARα activity. A larger population study
is needed to understand PPAR agonists antiatherogenic
properties. However, their adverse eﬀects should be taken
into considerations.
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